Sarah E. David

Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies

J. Dunne, B. Frohnert, Inish O'Doherty, 2022, Diabetologia.

Leveraging Real‐World Data for EMA Qualification of a Model‐Based Biomarker Tool to Optimize Type‐1 Diabetes Prevention Studies

J. Podichetty, K. Romero, Jackson K. Burton, 2022, Clinical pharmacology and therapeutics.

Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies

J. Dunne, B. Frohnert, Inish O'Doherty, 2022, Diabetologia.

Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies

J. Podichetty, K. Romero, M. Haller, 2023, CPT: pharmacometrics & systems pharmacology.

T1dCteGui: A User‐Friendly Clinical Trial Enrichment Tool to Optimize T1D Prevention Studies by Leveraging AI/ML Based Synthetic Patient Population

J. Podichetty, K. Romero, Nick Henscheid, 2023, Clinical pharmacology and therapeutics.